Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies
about
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisMast cells mediate malignant pleural effusion formation.CCL2 blockade augments cancer immunotherapy.Mutant KRAS promotes malignant pleural effusion formation.Changes in mouse uterine transcriptome in estrus and proestrus.Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.The role of macrophage class a scavenger receptors in a laser-induced murine choroidal neovascularization model.Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function
P2860
Q29614347-B8523BD6-094B-47D5-BFB4-54EDCBBE0405Q30657333-E9B41B73-80DD-43E9-A931-4EA9058CD204Q33651427-D0DAE5F0-80A5-44C6-B5B5-6AF928B238CBQ33716297-2A50F151-1D18-451A-845B-0108905557AFQ33826070-F4AD6AE5-CBBC-40EA-ABA5-8EEE6F1D0FF5Q34626551-8DBAA4A2-9604-4017-91F3-84C2FA3EE900Q34744555-7CDC021E-3474-4B38-9A38-AD56BF8BCBDCQ34911490-CF5E3815-26CD-41B9-9C31-F6044E72C546Q34963525-70C6A7BF-F85F-4109-992D-216B9BD4AA57Q36278280-3EDA0E48-4309-4059-90F8-CAA387C7421AQ38726039-F6CC4CA1-6E21-4F1E-850F-DD828DFB3B6CQ41861205-93F36834-BD0D-4248-B75D-BDDB847A5BB0
P2860
Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@ast
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@en
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@en-gb
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@nl
type
label
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@ast
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@en
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@en-gb
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@nl
prefLabel
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@ast
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@en
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@en-gb
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@nl
P2093
P921
P1433
P1476
Generation, characterization a ...... 12 (MCP-5) specific antibodies
@en
P2093
Brian Whitaker
Eilyn R Lacy
Elisabeth Kaiser
Linda A Snyder
Mark Tornetta
Nicole Stowell
Prabakaran Kesavan
P304
P407
P577
2007-01-01T00:00:00Z